tiprankstipranks

Ali J. Satvat Insider Profile

4 Followers
Ali J. Satvat, Director at BridgeBio Pharma, holds 169.98K shares in BridgeBio Pharma (Ticker: BBIO), holds 30.00K shares in Coherus Biosciences (Ticker: CHRS), holds 24.58M shares in Eidos Therapeutics (Ticker: EIDX).
tipranks
Ali J. Satvat

Ali J. Satvat
BridgeBio Pharma (BBIO)
Director

Ranked #21,951 out of 108,921 Corporate Insiders

Profitable Transactions

100%
3 out of 3 Profitable Transactions

Average Return

+38.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$13M
99.69%
0.31%
A breakdown of Ali J. Satvat's holdings

Insider Roles

BridgeBio Pharma
(BBIO)
Director
Coherus Biosciences
(CHRS)
Director
Roles that Ali J. Satvat holds in companies

Most Profitable Insider Trade

Stock:
Eidos Therapeutics
(EIDX)
Rating:Informative Buy
Date:May 29, 2019 - May 29, 2020
Return:+57.20%
The most profitable trade made by Ali J. Satvat

Ali J. Satvat's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
BridgeBio Pharma
Jun 24, 2026
Director
Uninformative Buy
$12.93M
Coherus Biosciences
Jun 09, 2026
Director
Uninformative Buy
$39.60K
EIDX
Eidos Therapeutics
Jul 08, 2019
Informative Buy
26.38M
$3.00B
List of latest transactions for each holding click on a transaction to see Ali J. Satvat's performance on stock

Ali J. Satvat insider profile FAQ

What is the percentage of profitable transactions made by Ali J. Satvat?
The percentage of profitable transactions made by Ali J. Satvat is 100%.
    What is the average return per transaction made by Ali J. Satvat?
    The average return per transaction made by Ali J. Satvat is 38.20%.
      What stocks does Ali J. Satvat hold?
      Ali J. Satvat holds: BBIO, CHRS, EIDX stocks.
        What was Ali J. Satvat’s latest transaction?
        Ali J. Satvat latest transaction was an Uninformative Buy of ―.
          What was Ali J. Satvat's most profitable transaction?
          Ali J. Satvat’s most profitable transaction was an Informative Buy of EIDX stock on May 29, 2019. The return on the trade was 57.20%.
            What is Ali J. Satvat's role in BridgeBio Pharma?
            Ali J. Satvat's role in BridgeBio Pharma is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.